前收市價 | 91.76 |
開市 | 91.14 |
買盤 | 0.00 x 0 |
賣出價 | 0.00 x 0 |
今日波幅 | 90.75 - 91.86 |
52 週波幅 | 80.60 - 105.18 |
成交量 | |
平均成交量 | 1,323,617 |
市值 | 113.801B |
Beta 值 (5 年,每月) | 0.44 |
市盈率 (最近 12 個月) | 21.20 |
每股盈利 (最近 12 個月) | 4.30 |
業績公佈日 | 2024年4月25日 |
遠期股息及收益率 | 3.76 (4.10%) |
除息日 | 2024年5月13日 |
1 年預測目標價 | 103.30 |
In this article, we will be taking a look at the 32 countries with the highest rates of diabetes. If you do not want to learn about the global diabetes market, head straight to the 5 Countries with the Highest Rates of Diabetes. The Global Diabetes Market and Its Implications The global diabetes market is […]
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript March 21, 2024 Innate Pharma S.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: At this time, I would like to welcome everyone to the Innate Pharma Full Year 2023 Financial […]
Mirador Therapeutics said on Thursday it had secured more than $400 million to develop precision medicines for immune-related diseases, in a rare, large early-stage fundraise. Easing inflationary pressures, increasing bets of a soft landing and promising data from drug trials are starting to boost the biotech funding market, which saw a downturn last year along with other industries. "This is one of the largest series A rounds, probably in history, certainly this year," Mirador CEO and founder Mark McKenna said, without disclosing the valuation at which the funds were raised or the breakdown of the amounts raised in the latest two rounds.